Urinary Incontinence - Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, “Urinary Incontinence - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the Urinary Incontinence (UI) therapeutics market. The report identifies the key trends shaping and driving the UI market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global UI therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global Urinary Incontinence (UI) therapeutics market was worth approximately $2.5 billion in 2009. In 2001 the market was valued at $1.4 billion and it grew at an approximate CAGR of 7.8% from 2001 to 2009. The global UI therapeutics market is expected to reach $3.4 billion by 2017 after growing at a CAGR of 3.5%. The impending patent expiries of Detrol and Enablex are the major reasons for the slow market growth expected from 2012 onwards. Presently the therapeutic regimen for UI is dominated by a range of muscarinic receptor antagonists (anticholinergic drugs) which include Detrol/Detrol LA, Ditropan, Enablex, Toviaz, Sanctura XR and VESIcare. This market is a significantly genericized market with many brands across the seven geographies.

Companies Mentioned:

Allergan Inc.
Astellas Pharma
Kissei Pharmaceuticals
Pfizer Inc.
[Fade out the market survey infos]

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 UI Therapeutics: Introduction 4
2.1 GlobalData Pipeline Report Guidance 5
3 UI Therapeutics: Market Characterization 6
3.1 UI Therapeutics Market Size 6
3.2 UI Therapeutics Market Forecast and CAGR 7
3.3 Drivers and Barriers for the UI Therapeutics Market 7
3.3.1 Drivers for the UI Therapeutics Market 8
3.3.2 Barriers for the UI Therapeutics Market 8
3.4 Opportunity and Unmet Need 8
3.5 Key Takeaway 9
4 UI Therapeutics Market: Competitive Assessment 10
4.1 Overview 10
4.2 Strategic Competitor Assessment 10
4.3 Product Portfolio for Major Marketed Products in the UI Therapeutics Market 11
4.3.1 Detrol/Detrol LA (Tolterodine tartrate) 11
4.3.2 Ditropan (Oxybutynin chloride) 12
4.3.3 Enablex (Darifenacin) 13
4.3.4 Sanctura XR (Trospium Chloride) 14
4.3.5 Toviaz (Fesoterodine Fumarate) 15
4.3.6 VESIcare (Solifenacin Succinate) 16
4.4 Key Takeaway 18
5 UI Therapeutics Market: Pipeline Assessment 19
5.1 Overview 19
5.1.1 Technology Trends Analytical Framework 19
5.2 UI Therapeutics—Promising Drugs under Clinical Development 20
5.3 Molecule Profiles for Promising Drugs under Clinical Development 21
5.3.1 Botulinum Toxin A 21
5.3.2 YM178 22
5.4 UI Therapeutics—Pipeline Assessment by Mechanism of Action 23
5.5 UI Therapeutics Market—Pipeline Assessment by Phase of Clinical Development 24
5.5.1 UI Therapeutics—Phase III Clinical Pipeline 24
5.5.2 UI Therapeutics—Phase II Clinical Pipeline 25
5.5.3 UI Therapeutics—Phase I Clinical Pipeline 25
5.5.4 UI Therapeutics—Preclinical Pipeline 26
5.6 Discontinued/Suspended Drugs for UI 26
6 UI Therapeutics: Implications for Future Market Competition 27
7 UI Therapeutics: Key Players in the UI Therapeutics Market 28
7.1 Allergan Inc. 28
7.1.1 Overview 28
7.1.2 Financial Performance 28
7.1.3 Business Description 29
7.1.4 Urology Pipeline Portfolio 30
7.1.5 UI Pipeline Portfolio 30
7.2 Astellas Pharma 31
7.2.1 Overview 31
7.2.2 Financial Performance 32
7.2.3 Business Description 32
7.2.4 Urology Pipeline Portfolio 33
7.2.5 UI Pipeline Portfolio 33
7.3 Kissei Pharmaceuticals 34
7.3.1 Overview 34
7.3.2 Financial Performance 34
7.3.3 Business Description 34
7.3.4 Urology Pipeline Portfolio 35
7.3.5 UI Pipeline Portfolio 35
7.4 Pfizer Inc. 35
7.4.1 Overview 35
7.4.2 Financial Performance 36
7.4.3 Business Description 36
7.4.4 Urology Pipeline Portfolio 37
7.4.5 UI Pipeline Portfolio 37
8 UI Therapeutics: Appendix 38
8.1 Definitions 38
8.2 Scope of Pipeline Research 38
8.3 Abbreviations 38
8.4 Research Methodology 39
8.4.1 Coverage 39
8.4.2 Secondary Research 40
8.4.3 Forecasting 40
8.4.4 Primary Research 42
8.4.5 Expert Panel Validation 43
8.5 Contact Us 43
8.6 Disclaimer 43
8.7 Sources 43
[Fade out table of contents]

Table 1: UI Therapeutics, Global, Market Revenue ($m), 2001–2009 6
Table 2: UI Therapeutics, Global, Market Forecast ($m), 2009–2017 7
Table 3: Clinical Study Details of Detrol LA, 2010 12
Table 4: Clinical Study Details of Ditropan XL, 2010 13
Table 5: Clinical Study Details of Enablex, 2010 14
Table 6: Clinical Study Details of Toviaz, 2010 16
Table 7: Major Marketed Products Comparison in the UI Therapeutics Market, 2010 18
Table 8: Most Promising Molecules under Clinical Development for UI, June 2010 20
Table 9: UI Therapeutics—Phase III Clinical Pipeline, 2010 24
Table 10: UI Therapeutics—Phase II Clinical Pipeline, 2010 25
Table 11: UI Therapeutics—Phase I Clinical Pipeline, 2010 25
Table 12: UI Therapeutics—Preclinical Pipeline, 2010 26
Table 13: UI Therapeutics—Discontinued Pipeline Products, 2010 26
Table 14: Allergan Inc.—Urology Pipeline Portfolio, July 2010 30
Table 15: Allergan Inc.—UI Pipeline Portfolio, July 2010 30
Table 16: Astellas Pharma—Urology Pipeline Portfolio, July 2010 33
Table 17: Astellas Pharma—UI Pipeline Portfolio, July 2010 33
Table 18: Kissei Pharmaceuticals—Urology Pipeline Portfolio, July 2010 35
Table 19: Kissei Pharmaceuticals—UI Pipeline Portfolio, July 2010 35
Table 20: Pfizer Inc.—Urology Pipeline Portfolio, July 2010 37
Table 21: Pfizer Inc.—UI Pipeline Portfolio, July 2010 37

Figure 1: UI Therapeutics, Global, Market Revenue ($m), 2001–2009 6
Figure 2: UI Therapeutics, Global, Market Forecast ($m), 2009–2017 7
Figure 3: Opportunity and Unmet Need in the UI Therapeutics Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for UI, 2010 10
Figure 5: Patients’ Perception of their Bladder Condition after Detrol LA Administration, 2006 11
Figure 6: Competitive Efficacy Study of VESIcare, 2004–2005 17
Figure 7: Technology Trends Analytic Framework of the UI Pipeline, 2010 19
Figure 8: Technology Trends Analytic Framework of the UI Pipeline—Description, 2010 20
Figure 9: UI Therapeutics—Clinical Pipeline by Mechanism of Action, 2010 23
Figure 10: UI Therapeutics—Clinical Pipeline by Phase of Development, 2010 24
Figure 11: UI Therapeutics, Implications for Future Market Competition, 2010 27
Figure 12: UI Therapeutics—Clinical Pipeline by Company, 2010 28
Figure 13: GlobalData Methodology 39
Figure 14: GlobalData Market Forecasting Model 42
[Fade out list of tables / figures]